Amphastar Pharmaceuticals (AMPH) Gross Margin (2016 - 2025)
Historic Gross Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 51.42%.
- Amphastar Pharmaceuticals' Gross Margin fell 18900.0% to 51.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.36%, marking a year-over-year decrease of 36200.0%. This contributed to the annual value of 51.08% for FY2024, which is 34100.0% down from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Gross Margin is 51.42%, which was down 18900.0% from 49.59% recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Gross Margin ranged from a high of 60.04% in Q3 2023 and a low of 43.63% during Q1 2021
- Its 5-year average for Gross Margin is 50.19%, with a median of 49.99% in 2025.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Gross Margin skyrocketed by 113300bps in 2023, and later plummeted by -75300bps in 2024.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Gross Margin stood at 46.52% in 2021, then rose by 13bps to 52.71% in 2022, then increased by 2bps to 53.98% in 2023, then decreased by -14bps to 46.45% in 2024, then rose by 11bps to 51.42% in 2025.
- Its Gross Margin was 51.42% in Q3 2025, compared to 49.59% in Q2 2025 and 49.99% in Q1 2025.